Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 1
1999 1
2000 4
2001 4
2002 6
2003 3
2004 7
2005 2
2006 4
2007 4
2008 2
2009 5
2010 6
2011 4
2012 4
2013 6
2014 3
2015 2
2016 5
2017 5
2018 7
2019 5
2020 8
2021 5
2022 14
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
Nose Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Yamamoto K, Makino T, Takahashi T, Kawashima A, Haruna M, Hirata M, Ueyama A, Iwahori K, Satoh T, Kurokawa Y, Eguchi H, Doki Y, Wada H. Nose Y, et al. Among authors: iwahori k. Cancer Immunol Immunother. 2023 Jan;72(1):169-181. doi: 10.1007/s00262-022-03240-2. Epub 2022 Jul 1. Cancer Immunol Immunother. 2023. PMID: 35776160
Ferritin in the field of nanodevices.
Yamashita I, Iwahori K, Kumagai S. Yamashita I, et al. Among authors: iwahori k. Biochim Biophys Acta. 2010 Aug;1800(8):846-57. doi: 10.1016/j.bbagen.2010.03.005. Epub 2010 Mar 12. Biochim Biophys Acta. 2010. PMID: 20227466 Review.
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8+ T cell cytotoxicity and proliferation.
Naito Y, Koyama S, Masuhiro K, Hirai T, Uenami T, Inoue T, Osa A, Machiyama H, Watanabe G, Sax N, Villa J, Kinugasa-Katayama Y, Nojima S, Yaga M, Hosono Y, Okuzaki D, Satoh S, Tsuda T, Nakanishi Y, Suga Y, Morita T, Fukushima K, Nishide M, Shiroyama T, Miyake K, Iwahori K, Hirata H, Nagatomo I, Yano Y, Tamiya M, Kumagai T, Takemoto N, Inohara H, Yamasaki S, Yamashita K, Aoshi T, Akbay EA, Hosen N, Shintani Y, Takamatsu H, Mori M, Takeda Y, Kumanogoh A. Naito Y, et al. Among authors: iwahori k. Sci Adv. 2023 May 19;9(20):eade0718. doi: 10.1126/sciadv.ade0718. Epub 2023 May 19. Sci Adv. 2023. PMID: 37205755 Free PMC article.
T cell immunity in interstitial lung disease with non-small cell lung cancer patients.
Isono T, Iwahori K, Yanagawa M, Yamamoto Y, Tone M, Haruna M, Hirata M, Fukui E, Kimura T, Kanou T, Ose N, Funaki S, Takeda Y, Morii E, Kumanogoh A, Shintani Y, Wada H. Isono T, et al. Among authors: iwahori k. Lung Cancer. 2023 Aug;182:107278. doi: 10.1016/j.lungcan.2023.107278. Epub 2023 Jun 9. Lung Cancer. 2023. PMID: 37321075
PD-1 expression on tumor cells: a new target for cancer therapy.
Tone M, Iwahori K. Tone M, et al. Among authors: iwahori k. Transl Lung Cancer Res. 2024 Jan 31;13(1):186-189. doi: 10.21037/tlcr-23-683. Epub 2024 Jan 25. Transl Lung Cancer Res. 2024. PMID: 38404990 Free PMC article. No abstract available.
The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer.
Haruna M, Ueyama A, Yamamoto Y, Hirata M, Goto K, Yoshida H, Higuchi N, Yoshida T, Kidani Y, Nakamura Y, Nagira M, Kawashima A, Iwahori K, Shintani Y, Ohkura N, Wada H. Haruna M, et al. Among authors: iwahori k. Sci Rep. 2022 Mar 30;12(1):5377. doi: 10.1038/s41598-022-09458-5. Sci Rep. 2022. PMID: 35354899 Free PMC article.
110 results